Skip to main content
Cardiology Journal logoLink to Cardiology Journal
letter
. 2026 Mar 13;33:e00226024. doi: 10.5603/cj.109434

Lipoprotein(a) and clinical characteristics of Polish patients hospitalized in a tertiary referral hospital — an observational, cross-sectional study

Julia M Umińska 1,✉, Jakub Ratajczak 1, Jacek Kubica 1
PMCID: PMC13170441  PMID: 41823266

To the Editor,

The assessment of lipoprotein(a) [Lp(a)] as an integral element of cardiovascular risk evaluation is gaining increasing importance, particularly in light of the forthcoming therapeutic options specifically targeting this lipoprotein. Therefore, we would like to congratulate the authors for drawing attention to this clinically relevant topic in their recent article [1]. As our research group is also actively involved in studies focusing on Lp(a) [2–5], we follow with interest publications addressing this issue.

When conducting epidemiological research, it is crucial to interpret results in the context of study limitations. In our opinion, the most important limitation of the study by Saniewski et al. [1] lies in the relatively small sample size, which raises concerns regarding the robustness of the conclusions. The compared groups differed substantially in several demographic characteristics, and the lack of statistical significance in these comparisons likely reflects insufficient statistical power rather than true similarity. We believe that further continuation of this project, with a larger sample size, will help address this limitation and allow the use of propensity score matching, thereby increasing the reliability of future results.

In this context, we were also intrigued by the lipid profile data, which appear somewhat inconsistent and therefore merit clarification by the authors. Specifically, in the group with elevated Lp(a), mean low density lipoprotein (LDL) cholesterol was slightly higher, whereas the mean non-high density lipoprotein (HDL) cholesterol was paradoxically lower. Since both Lp(a) and LDL-cholesterol contribute to non-HDL-cholesterol, how should this finding be interpreted? Could it have implications for the overall conclusions of the study? We believe that this interesting observation deserves further discussion and potentially more detailed analysis in future work.

Acknowledgments

None.

Footnotes

Conflict of interest: The authors have no competing interest to declare.

Supplementary material: None.

Funding: None.

References

  • 1.Saniewski T, Procyk G, Zimodro J, et al. Lipoprotein(a) and clinical characteristics of Polish patients hospitalized in a tertiary referral hospital - an observational, cross-sectional study. Cardiol J. 2026;33:e00226010. doi: 10.5603/cj.108082. Epub 2025 Oct 16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Ziółkowski M, Ratajczak J, Obońska K, et al. Lipid profile and the variables associated with control of selected lipid parameters in patients of a large multi-specialist hospital in Poland — the Jurasz Lipid Study (JLS) Lipids Health Dis. 2025;24(1):300. doi: 10.1186/s12944-025-02712-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Ratajczak J, Kubica A, Pietrzykowski Ł, et al. Lipoprotein (a) and the occurrence of lipid disorders and other cardiovascular risk factors in patients without diagnosed cardiovascular disease. J Clin Med. 2024;13(16) doi: 10.3390/jcm13164649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Navarese EP, Vine D, Proctor S, et al. Independent causal effect of remnant cholesterol on atherosclerotic cardiovascular outcomes: a mendelian randomization study. Arterioscler Thromb Vasc Biol. 2023;43(9):e373–e380. doi: 10.1161/ATVBAHA.123.319297. [DOI] [PubMed] [Google Scholar]
  • 5.Kubica J. Should dual antiplatelet treatment be guided by lipoprotein(a) concentration? Cardiol J. 2024;31(2):363–364. doi: 10.5603/cj.97979. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cardiology Journal are provided here courtesy of Via Medica sp. z o.o. sp. k.

RESOURCES